RELMADA THERAPEUTICS INC's ticker is RLMD and the CUSIP is 75955J402. A total of 86 filers reported holding RELMADA THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 2.25 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $27 | +8.0% | 9,300 | -6.1% | 0.00% | 0.0% |
| Q2 2023 | $25 | +4.2% | 9,900 | 0.0% | 0.00% | +50.0% |
| Q1 2023 | $24 | -78.4% | 9,900 | -85.7% | 0.00% | -77.8% |
| Q4 2022 | $111 | -100.0% | 69,400 | +263.7% | 0.01% | -72.7% |
| Q3 2022 | $478,000 | +602.9% | 19,082 | -10.7% | 0.03% | +560.0% |
| Q2 2022 | $68,000 | -84.1% | 21,367 | -61.4% | 0.01% | -77.3% |
| Q1 2022 | $428,000 | +10600.0% | 55,346 | +18348.7% | 0.02% | – |
| Q4 2021 | $4,000 | -91.5% | 300 | -93.5% | 0.00% | -100.0% |
| Q3 2021 | $47,000 | -13.0% | 4,600 | -17.9% | 0.00% | -33.3% |
| Q2 2021 | $54,000 | +125.0% | 5,600 | +700.0% | 0.00% | +200.0% |
| Q1 2021 | $24,000 | +20.0% | 700 | -84.3% | 0.00% | 0.0% |
| Q4 2020 | $20,000 | -4.8% | 4,460 | +53.8% | 0.00% | – |
| Q3 2020 | $21,000 | -36.4% | 2,900 | -68.1% | 0.00% | -100.0% |
| Q2 2020 | $33,000 | -2.9% | 9,100 | +152.8% | 0.00% | 0.0% |
| Q1 2020 | $34,000 | +88.9% | 3,600 | +38.5% | 0.00% | +100.0% |
| Q4 2019 | $18,000 | – | 2,600 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| VR Adviser, LLC | 2,270,072 | $61,269,000 | 9.93% |
| GREAT POINT PARTNERS LLC | 790,000 | $21,322,000 | 5.15% |
| ACUTA CAPITAL PARTNERS, LLC | 342,000 | $9,231,000 | 4.31% |
| COWEN AND COMPANY, LLC | 1,164,361 | $31,426,000 | 3.02% |
| Altium Capital Management LP | 206,000 | $5,560,000 | 1.86% |
| BVF INC/IL | 1,647,400 | $44,463,000 | 1.78% |
| RTW INVESTMENTS, LP | 2,540,074 | $68,557,000 | 1.42% |
| Vivo Capital, LLC | 705,882 | $19,052,000 | 1.31% |
| RA Capital Management | 2,000,000 | $53,980,000 | 1.18% |
| SPHERA FUNDS MANAGEMENT LTD. | 291,252 | $7,861,000 | 1.11% |